A role for orexin in cytotoxic chemotherapy-induced fatigue
- 1 March 2014
- journal article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 37, 84-94
Abstract
No abstract availableKeywords
Funding Information
- NIH F31NR01329901 to KBW
- NINR R01NR012479 to LJW
- NIH R01 DK70333 to DLM
This publication has 79 references indexed in Scilit:
- Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicinCancer Biology & Therapy, 2013
- Controlled Cortical Impact Traumatic Brain Injury Acutely Disrupts Wakefulness and Extracellular Orexin Dynamics as Determined by Intracerebral Microdialysis in MiceJournal of Neurotrauma, 2012
- Trial watchOncoImmunology, 2012
- Immune system to brain signaling: Neuropsychopharmacological implicationsPharmacology & Therapeutics, 2011
- Hypothalamic regulation of sleep and circadian rhythmsNature, 2005
- Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Fos Expression in Orexin Neurons Varies with Behavioral StateThe Journal of Neuroscience, 2001
- Fatique Patterns Observed in Patients Receiving Chemotherapy and RadiotherapyCancer Investigation, 2000
- Lipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAsBrain Research, 1998
- A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancerBreast Cancer Research and Treatment, 1983